1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
BIOLASE, Inc.

BIOLASE, Inc.

BIOL
BIOLASE, Inc.US flagNASDAQ Capital Market
0.02
USD
+0.00
- -
731,942.00Market Cap

Total Valuation

BIOLASE, Inc. carries a market capitalization of 731,942.00, placing it among publicly traded companies globally. Its enterprise value stands at 17.21M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap731,942.00
Enterprise Value17.21M

Share Statistics

BIOLASE, Inc. currently has 36.60M shares outstanding.

Shares Outstanding36.60M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 0.04, and the price-to-book ratio stands at -0.01.

PE RatioN/A
PS Ratio0.04
PB Ratio-0.01
P/TBV Ratio-0.24
P/FCF Ratio-0.15
P/OCF Ratio-0.15

Enterprise Valuation

EV / Sales0.37
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

BIOLASE, Inc. maintains a current ratio of 0.63, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -357.57, indicating conservative leverage, while an interest coverage ratio of -4.51 demonstrates limited ability to service its debt obligations.

Current Ratio0.63
Quick Ratio0.23
Debt / Equity-357.57
Debt / EBITDA-1.72
Interest Coverage-4.51

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-48.61
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.55

Taxes

Income Tax36,000.00
Effective Tax RateN/A

Stock Price Statistics

BIOLASE, Inc.'s stock has declined approximately -98.80952% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.28.

Beta (5Y)N/A
52-Week Price Change-98.80952%
50-Day Moving Average0.06
200-Day Moving Average0.28
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, BIOLASE, Inc. generated 46.03M in revenue and converted that into -16.04M in net income, yielding earnings per share of -0.55. EBITDA reached -10.90M, while operating income came in at -13.52M.

Revenue46.03M
Gross Profit15.85M
Operating Income-13.52M
Pretax Income-16.00M
Net Income-16.04M
EBITDA-10.90M
EBIT-13.52M
Earnings Per Share (EPS)-0.55

Balance Sheet

BIOLASE, Inc. holds 3.44M in cash and equivalents against 18.69M in total debt, resulting in a net debt position of 14.18M. Total book value stands at -327.47M, with working capital of -11.43M providing operational flexibility.

Cash & Cash Equivalents3.44M
Total Debt18.69M
Net Debt14.18M
Equity (Book Value)-327.47M
Book Value Per Share-11.25
Working Capital-11.43M

Cash Flow

BIOLASE, Inc. produced -13.43M in operating cash flow over the past twelve months. After subtracting -252,000.00 in capital expenditures, free cash flow totaled -13.68M - equivalent to -0.47 per share.

Operating Cash Flow-13.43M
Capital Expenditures-252,000.00
Free Cash Flow-13.68M
FCF Per Share-0.47

Margins

BIOLASE, Inc. operates with a gross margin of 34.44, reflecting its pricing power and cost economics. The operating margin of -29.37 and net profit margin of -34.84 provide insight into operational efficiency.

Gross Margin34.44
Operating Margin-29.37
Pretax Margin-34.77
Profit Margin-34.84
EBITDA Margin-23.68

Dividends & Yields

The company's payout ratio of -0.44 indicates the proportion of earnings distributed to shareholders.

Dividend Per ShareN/A
Dividend YieldN/A
Payout Ratio-0.44
Shareholder Yield-438.09
FCF Yield-671.61

Stock Splits

BIOLASE, Inc.'s most recent stock split took place on July 28, 2023 with a 100:1 split ratio.

Last Split Date7/28/2023
Split Ratio100:1

Scores

BIOLASE, Inc. posts an Altman Z-Score of -19.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-19.33